Cerevel Therapeutics' Phase 3 trial of tavapadon for Parkinson's disease shows increased "on" time with reduced dyskinesia when used with levodopa.
Cerevel Therapeutics reported positive results from its Phase 3 trial of tavapadon, a potential Parkinson's disease treatment. Tavapadon, when used with levodopa, increased patients' "on" time without troublesome dyskinesia by 1.1 hours compared to levodopa and a placebo. Cerevel plans to share additional data and present full results at medical meetings, supporting regulatory submissions for tavapadon as a Parkinson's treatment.
April 18, 2024
4 Articles